In silico exploration of the fingerprints triggering modulation of glutaminyl cyclase inhibition for the treatment of Alzheimer’s disease using SMILES based attributes in Monte Carlo optimization

References

• Ahmadi, S. (2020). Mathematical modeling of cytotoxicity of metal oxide nanoparticles using the index of ideality correlation criteria. Chemosphere, 242, 125192. https://doi.org/https://doi.org/10.1016/j.chemosphere.2019.125192
   PubMed Web of Science ®Google Scholar
• Ahmadi, S., Ghanbari, H., Lotfi, S., & Azimi, N. (2020). Predictive QSAR modeling for the antioxidant activity of natural compounds derivatives based on Monte Carlo method. Molecular Diversity. https://doi.org/https://doi.org/10.1007/s11030-019-10026-9
   Google Scholar
• Ahmadi, S., Mardinia, F., Azimi, N., Qomi, M., & Balali, E. (2019). Prediction of chalcone derivative cytotoxicity activity against MCF-7 human breast cancer cell by Monte Carlo method. Journal of Molecular Structure, 1181, 305–311. https://doi.org/https://doi.org/10.1016/j.molstruc.2018.12.089
   Web of Science ®Google Scholar
• Alzheimer’s-Association. (2017). Beta-amyloid and the amyloid hypothesis. https://www.alz.org/national/documents/topicsheet_betaamyloid.pdf
   Google Scholar
• Alzheimer’s-Association. (2018). 2018 Alzheimer's disease facts and figures. Alzheimer's & Dementia, 14(3), 367–429. https://doi.org/https://doi.org/10.1016/j.jalz.2018.02.001
   Web of Science ®Google Scholar
• Alzheimer’s-Disease-International. (2019). World Alzheimer Report 2019: Attitudes to dementia. Alzheimer’s Disease International. https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf
   Google Scholar
• Amin, S. A., Bhargava, S., Adhikari, N., Gayen, S., & Jha, T. (2018). Exploring pyrazolo[3,4-d]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: A predictive approach combining comparative validated multiple molecular modelling techniques. Journal of Biomolecular Structure & Dynamics, 36(3), 590–608. https://doi.org/https://doi.org/10.1080/07391102.2017.1288659
   PubMed Web of Science ®Google Scholar
• Benfenati, E., Toropov, A. A., Toropova, A. P., Manganaro, A., & Gonella Diaza, R. (2011). CORAL Software: QSAR for anticancer agents. Chemical Biology & Drug Design, 77(6), 471–476. https://doi.org/https://doi.org/10.1111/j.1747-0285.2011.01117.x
   PubMed Web of Science ®Google Scholar
• Bloom, G. S. (2014). Amyloid-β and Tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurology, 71(4), 505–508. https://doi.org/https://doi.org/10.1001/jamaneurol.2013.5847
   PubMed Web of Science ®Google Scholar
• Bridel, C., Hoffmann, T., Meyer, A., Durieux, S., Koel-Simmelink, M. A., Orth, M., Scheltens, P., Lues, I., & Teunissen, C. E. (2017). Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients. Alzheimer's Research & Therapy, 9(1), 38. https://doi.org/https://doi.org/10.1186/s13195-017-0266-6
   PubMedGoogle Scholar
• Buchholz, M., Hamann, A., Aust, S., Brandt, W., Böhme, L., Hoffmann, T., Schilling, S., Demuth, H.-U., & Heiser, U. (2009). Inhibitors for human glutaminyl cyclase by structure based design and bioisosteric replacement. Journal of Medicinal Chemistry, 52(22), 7069–7080. https://doi.org/https://doi.org/10.1021/jm900969p
   PubMed Web of Science ®Google Scholar
• Buchholz, M., Heiser, U., Schilling, S., Niestroj, A. J., Zunkel, K., & Demuth, H.-U. (2006). The first potent inhibitors for human glutaminyl cyclase: Synthesis and structure-activity relationship. Journal of Medicinal Chemistry, 49(2), 664–677. https://doi.org/https://doi.org/10.1021/jm050756e
   PubMed Web of Science ®Google Scholar
• Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017). Amyloid beta: Structure, biology and structure-based therapeutic development. Acta Pharmacologica Sinica, 38(9), 1205–1235. https://doi.org/https://doi.org/10.1038/aps.2017.28
   PubMed Web of Science ®Google Scholar
• Chirico, N., & Gramatica, P. (2011). Real external predictivity of QSAR models: How to evaluate it? Comparison of different validation criteria and proposal of using the concordance correlation coefficient. Journal of Chemical Information and Modeling, 51(9), 2320–2335. https://doi.org/https://doi.org/10.1021/ci200211n
   PubMed Web of Science ®Google Scholar
• Coimbra, J. R. M., Sobral, P. J. M., Santos, A. E., Moreira, P. I., & Salvador, J. A. R. (2019). An overview of glutaminyl cyclase inhibitors for Alzheimer's disease. Future Medicinal Chemistry, 11(24), 3179–3194. https://doi.org/https://doi.org/10.4155/fmc-2019-0163
   PubMed Web of Science ®Google Scholar
• Dassault-Systèmes-BIOVIA. (2019). Discovery studio. Dassault Systèmes.
   Google Scholar
• Du, X., Wang, X., & Geng, M. (2018). Alzheimer's disease hypothesis and related therapies. Translational Neurodegeneration, 7(1), 2. https://doi.org/https://doi.org/10.1186/s40035-018-0107-y
   PubMedGoogle Scholar
• Duhan, M., Singh, R., Devi, M., Sindhu, J., Bhatia, R., Kumar, A., & Kumar, P. (2019). Synthesis, molecular docking and QSAR study of thiazole clubbed pyrazole hybrid as alpha-amylase inhibitor. Journal of Biomolecular Structure and Dynamics, 1–17. https://doi.org/https://doi.org/10.1080/07391102.2019.1704885
   Google Scholar
• ENV/JM/MONO, O. D. J. (2007). Guidance Document on the Validation of (Quantitative)  Structure–Activity Relationships [(Q) SARs] Models, 2. Paris: OECD Publishing.
   Google Scholar
• Golbraikh, A., & Tropsha, A. (2002). Beware of q2!. Journal of Molecular Graphics and Modelling, 20(4), 269–276. https://doi.org/https://doi.org/10.1016/S1093-3263(01)00123-1 https://doi.org/https://doi.org/10.1016/s1093-3263(01)00123-1
   PubMed Web of Science ®Google Scholar
• Golbraikh, A., Wang, X. S., Zhu, H., & Tropsha, A. (2012). Predictive QSAR modeling: Methods and applications in drug discovery and chemical risk assessment. In J. Leszczynski (Ed.), Handbook of computational chemistry (pp. 1309–1342). Springer Netherlands.
   Google Scholar
• Gramatica, P. (2007). Principles of QSAR models validation: Internal and external. QSAR & Combinatorial Science, 26(5), 694–701. https://doi.org/https://doi.org/10.1002/qsar.200610151
   Google Scholar
• Gramatica, P. (2013). On the development and validation of QSAR models. In B. Reisfeld & A. N. Mayeno (Eds.), Computational toxicology: Volume II (pp. 499–526). Humana Press.
   Google Scholar
• Harigaya, Y., Saido, T. C., Eckman, C. B., Prada, C.-M., Shoji, M., & Younkin, S. G. (2000). Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochemical and Biophysical Research Communications, 276(2), 422–427. https://doi.org/https://doi.org/10.1006/bbrc.2000.3490
   PubMed Web of Science ®Google Scholar
• Hennekens, C. H., A., Bensadon, B., Zivin, R., & Gaziano, J. M. (2015). Hypothesis: Glutaminyl cyclase inhibitors decrease risks of Alzheimer's disease and related dementias. Expert Review of Neurotherapeutics, 15(11), 1245–1248. https://doi.org/https://doi.org/10.1586/14737175.2015.1088784
   PubMed Web of Science ®Google Scholar
• Hillen, H. (2019). The Beta Amyloid Dysfunction (BAD) hypothesis for Alzheimer's disease. Frontiers in Neuroscience, 13(1154), 1154. https://doi.org/https://doi.org/10.3389/fnins.2019.01154
   PubMedGoogle Scholar
• Hoffmann, T., Meyer, A., Heiser, U., Kurat, S., Böhme, L., Kleinschmidt, M., Bühring, K.-U., Hutter-Paier, B., Farcher, M., Demuth, H.-U., Lues, I., & Schilling, S. (2017). Glutaminyl cyclase inhibitor PQ912 improves cognition in mouse models of Alzheimer's disease-studies on relation to effective target occupancy. Journal of Pharmacology and Experimental Therapeutics, 362(1), 119–130. https://doi.org/https://doi.org/10.1124/jpet.117.240614
   PubMed Web of Science ®Google Scholar
• Huang, K.-F., Liaw, S.-S., Huang, W.-L., Chia, C.-Y., Lo, Y.-C., Chen, Y.-L., & Wang, A. H.-J. (2011). Structures of human golgi-resident glutaminyl cyclase and its complexes with inhibitors reveal a large loop movement upon inhibitor binding. The Journal of Biological Chemistry, 286(14), 12439–12449. https://doi.org/https://doi.org/10.1074/jbc.M110.208595
   PubMed Web of Science ®Google Scholar
• Islam, M. L., & Gupta, G. K. (2018). Application of Monte Carlo algorithm to explore simplified molecular-input line-entry system based molecular descriptors of BACE1 inhibitors for therapeutic application in Alzheimer’s disease. International Journal of Computer Applications, 182(11), 40–47. https://doi.org/https://doi.org/10.5120/ijca2018917745
   Google Scholar
• Jain, S., Amin, S. A., Adhikari, N., Jha, T., & Gayen, S. (2020). Good and bad molecular fingerprints for human rhinovirus 3C protease inhibition: Identification, validation, and application in designing of new inhibitors through Monte Carlo-based QSAR study. Journal of Biomolecular Structure & Dynamics, 38(1), 66–77. https://doi.org/https://doi.org/10.1080/07391102.2019.1566093
   PubMed Web of Science ®Google Scholar
• Jain, S., Bhardwaj, B., Amin, S. A., Adhikari, N., Jha, T., & Gayen, S. (2020). Exploration of good and bad structural fingerprints for inhibition of indoleamine-2,3-dioxygenase enzyme in cancer immunotherapy using Monte Carlo optimization and Bayesian classification QSAR modeling. Journal of Biomolecular Structure & Dynamics, 38(6), 1683–1696. https://doi.org/https://doi.org/10.1080/07391102.2019.1615000
   PubMed Web of Science ®Google Scholar
• Kumar, A., & Chauhan, S. (2017). QSAR differential model for prediction of SIRT1 modulation using Monte Carlo method. Drug Research, 67(3), 156–162. https://doi.org/https://doi.org/10.1055/s-0042-119725
   Web of Science ®Google Scholar
• Kumar, A., Sindhu, J., & Kumar, P. (2020). In-silico identification of fingerprint of pyrazolyl sulfonamide responsible for inhibition of N-myristoyltransferase using Monte Carlo method with index of ideality of correlation. Journal of Biomolecular Structure and Dynamics, 1–12. https://doi.org/https://doi.org/10.1080/07391102.2020.1784286
   Google Scholar
• Kumar, A., Singh, A. & Ekavali, (2015). A review on Alzheimer's disease pathophysiology and its management: An update. Pharmacological Reports, 67(2), 195–203. https://doi.org/https://doi.org/10.1016/j.pharep.2014.09.004
   PubMed Web of Science ®Google Scholar
• Kumar, P., & Kumar, A. (2018). Monte Carlo method based QSAR studies of mer kinase inhibitors in compliance with OECD principles. Drug Research, 68(4), 189–195. https://doi.org/https://doi.org/10.1055/s-0043-119288
   Web of Science ®Google Scholar
• Kumar, P., & Kumar, A. (2019). Nucleobase sequence based building up of reliable QSAR models with the index of ideality correlation using Monte Carlo method. Journal of Biomolecular Structure and Dynamics, 38(11), 3296–3306. https://doi.org/https://doi.org/10.1080/07391102.2019.1656109
   Google Scholar
• Kumar, P., & Kumar, A. (2020). CORAL: QSAR models of CB1 cannabinoid receptor inhibitors based on local and global SMILES attributes with the index of ideality of correlation and the correlation contradiction index. Chemometrics and Intelligent Laboratory Systems, 200, 103982. https://doi.org/https://doi.org/10.1016/j.chemolab.2020.103982
   Web of Science ®Google Scholar
• Kuo, Y.-M., Emmerling, M. R., Woods, A. S., Cotter, R. J., & Roher, A. E. (1997). Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits . Biochemical and Biophysical Research Communications, 237(1), 188–191. https://doi.org/https://doi.org/10.1006/bbrc.1997.7083
   PubMed Web of Science ®Google Scholar
• Lanctôt, K. L., Amatniek, J., Ancoli-Israel, S., Arnold, S. E., Ballard, C., Cohen-Mansfield, J., Ismail, Z., Lyketsos, C., Miller, D. S., Musiek, E., Osorio, R. S., Rosenberg, P. B., Satlin, A., Steffens, D., Tariot, P., Bain, L. J., Carrillo, M. C., Hendrix, J. A., Jurgens, H., & Boot, B. (2017). Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms. Alzheimer's & Dementia (New York, N.Y.), 3(3), 440–449. https://doi.org/https://doi.org/10.1016/j.trci.2017.07.001
   PubMedGoogle Scholar
• Lao, K., Ji, N., Zhang, X., Qiao, W., Tang, Z., & Gou, X. (2019). Drug development for Alzheimer's disease: Review. Journal of Drug Targeting, 27(2), 164–173. https://doi.org/https://doi.org/10.1080/1061186X.2018.1474361
   PubMed Web of Science ®Google Scholar
• Li, X.-L., Hu, N., Tan, M.-S., Yu, J.-T., & Tan, L. (2014). Behavioral and psychological symptoms in Alzheimer's disease. BioMed Research International, 2014, 927804. https://doi.org/https://doi.org/10.1155/2014/927804
   PubMed Web of Science ®Google Scholar
• Manisha, Chauhan, S., Kumar, P., & Kumar, A. (2019). Development of prediction model for fructose- 1,6- bisphosphatase inhibitors using the Monte Carlo method. SAR and QSAR in Environmental Research, 30(3), 145–159. https://doi.org/https://doi.org/10.1080/1062936X.2019.1568299
   PubMed Web of Science ®Google Scholar
• Marvin-Sketch-v.14.11.17.0. (2014). ChemAxon, XhemAxon KFT. Hungary.
   Google Scholar
• Mitra, A., & Dey, B. (2013). Therapeutic interventions in Alzheimer disease. In U. Kishore (Ed.), Neurodegenerative diseases. IntechOpen. https://www.intechopen.com/books/neurodegenerative-diseases/therapeutic-interventions-in-alzheimer-disease.
   Google Scholar
• Nimbhal, M., Bagri, K., Kumar, P., & Kumar, A. (2020). The index of ideality of correlation: A statistical yardstick for better QSAR modeling of glucokinase activators. Structural Chemistry, 31(2), 831–839. https://doi.org/https://doi.org/10.1007/s11224-019-01468-w
   Web of Science ®Google Scholar
• O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011). Open Babel: An open chemical toolbox. Journal of Cheminformatics, 3(1), 33. https://doi.org/https://doi.org/10.1186/1758-2946-3-33
   PubMed Web of Science ®Google Scholar
• Ojha, P. K., Mitra, I., Das, R. N., & Roy, K. (2011). Further exploring rm2 metrics for validation of QSPR models. Chemometrics and Intelligent Laboratory Systems, 107(1), 194–205. https://doi.org/https://doi.org/10.1016/j.chemolab.2011.03.011
   Web of Science ®Google Scholar
• Pedretti, A., Villa, L., & Vistoli, G. (2002). VEGA: A versatile program to convert, handle and visualize molecular structure on Windows-based PCs. J. Mol. Graph. Model, 21(1), 47–49. https://doi.org/https://doi.org/10.1016/s1093-3263(02)00123-7
   PubMed Web of Science ®Google Scholar
• Ramsbeck, D., Buchholz, M., Koch, B., Böhme, L., Hoffmann, T., Demuth, H.-U., & Heiser, U. (2013). Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold. Journal of Medicinal Chemistry, 56(17), 6613–6625. https://doi.org/https://doi.org/10.1021/jm4001709
   PubMed Web of Science ®Google Scholar
• Ricciarelli, R., & Fedele, E. (2017). The amyloid cascade hypothesis in Alzheimer's disease: It's time to change our mind. Current Neuropharmacology, 15(6), 926–935. https://doi.org/https://doi.org/10.2174/1570159X15666170116143743
   PubMed Web of Science ®Google Scholar
• Roy, K. (2017). MLR Plus Validation. Kolkata, India: Jadhavpur University. Retrieved from http://dtclab.webs.com/software-tools and http://teqip.jdvu.ac.in/QSAR_Tools/
   Google Scholar
• Roy, K., & Kar, S. (2014). The rm2 metrics and regression through origin approach: Reliable and useful validation tools for predictive QSAR models (Commentary on 'Is regression through origin useful in external validation of QSAR models?'). European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences, 62, 111–114. https://doi.org/https://doi.org/10.1016/j.ejps.2014.05.019
   PubMed Web of Science ®Google Scholar
• Roy, K., Das, R. N., Ambure, P., & Aher, R. B. (2016). Be aware of error measures. Further studies on validation of predictive QSAR models. Chemometrics and Intelligent Laboratory Systems, 152, 18–33. https://doi.org/https://doi.org/10.1016/j.chemolab.2016.01.008
   Web of Science ®Google Scholar
• Roy, K., Kar, S., & Ambure, P. (2015). On a simple approach for determining applicability domain of QSAR models. Chemometrics and Intelligent Laboratory Systems, 145, 22–29. https://doi.org/https://doi.org/10.1016/j.chemolab.2015.04.013
   Web of Science ®Google Scholar
• Roy, K., Kar, S., & Das, R. N. (2015). Chapter 7 - Validation of QSAR models. In K. Roy, S. Kar, & R. N. Das (Eds.), Understanding the basics of QSAR for applications in pharmaceutical sciences and risk assessment (pp. 231–289). Academic Press.
   Google Scholar
• Roy, P. P., Leonard, J. T., & Roy, K. (2008). Exploring the impact of size of training sets for the development of predictive QSAR models. Chemometrics and Intelligent Laboratory Systems, 90(1), 31–42. https://doi.org/https://doi.org/10.1016/j.chemolab.2007.07.004
   Web of Science ®Google Scholar
• Scheltens, P., Hallikainen, M., Grimmer, T., Duning, T., Gouw, A. A., Teunissen, C. E., Wink, A. M., Maruff, P., Harrison, J., van Baal, C. M., Bruins, S., Lues, I., & Prins, N. D. (2018). Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: Results of a randomized, double-blind, placebo-controlled phase 2a study . Alzheimer's Research & Therapy, 10(1), 107. https://doi.org/https://doi.org/10.1186/s13195-018-0431-6
   PubMedGoogle Scholar
• Schilling, S., Zeitschel, U., Hoffmann, T., Heiser, U., Francke, M., Kehlen, A., Holzer, M., Hutter-Paier, B., Prokesch, M., Windisch, M., Jagla, W., Schlenzig, D., Lindner, C., Rudolph, T., Reuter, G., Cynis, H., Montag, D., Demuth, H.-U., & Rossner, S. (2008). Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology. Nature Medicine, 14(10), 1106–1111. https://doi.org/https://doi.org/10.1038/nm.1872
   PubMed Web of Science ®Google Scholar
• Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine, 8(6), 595–608. https://doi.org/https://doi.org/10.15252/emmm.201606210
   PubMed Web of Science ®Google Scholar
• Toropov, A. A., & Toropova, A. P. (2020). The Monte Carlo method as a tool to build up predictive QSPR/QSAR. Current Computer-Aided Drug Design, 16(3), 197–206. https://doi.org/https://doi.org/10.2174/1573409915666190328123112
   PubMed Web of Science ®Google Scholar
• Toropov, A. A., Toropova, A. P., Raitano, G., & Benfenati, E. (2019). CORAL: Building up QSAR models for the chromosome aberration test. Saudi Journal of Biological Sciences, 26(6), 1101–1106. https://doi.org/https://doi.org/10.1016/j.sjbs.2018.05.013
   PubMed Web of Science ®Google Scholar
• Toropov, A. A., Toropova, A. P., Selvestrel, G., & Benfenati, E. (2019). Idealization of correlations between optimal simplified molecular input-line entry system-based descriptors and skin sensitization. SAR and QSAR in Environmental Research, 30(6), 447–455. https://doi.org/https://doi.org/10.1080/1062936X.2019.1615547
   PubMed Web of Science ®Google Scholar
• Toropova, A. P., Toropov, A. A., Beeg, M., Gobbi, M., & Salmona, M. (2017). Utilization of the Monte Carlo method to build up QSAR models for hemolysis and cytotoxicity of antimicrobial peptides. Current Drug Discovery Technologies, 14(4), 229–243. https://doi.org/https://doi.org/10.2174/1570163814666170525114128
   PubMedGoogle Scholar
• Toropova, A. P., Toropov, A. A., Veselinović, A. M., Veselinović, J. B., Leszczynska, D., & Leszczynski, J. (2016). Monte Carlo-based quantitative structure-activity relationship models for toxicity of organic chemicals to Daphnia magna. Environmental Toxicology and Chemistry, 35(11), 2691–2697. https://doi.org/https://doi.org/10.1002/etc.3466
   PubMed Web of Science ®Google Scholar
• Toropova, M. A., Toropov, A. A., Raška, I., & Rašková, M. (2015). Searching therapeutic agents for treatment of Alzheimer disease using the Monte Carlo method. Computers in Biology and Medicine, 64, 148–154. https://doi.org/https://doi.org/10.1016/j.compbiomed.2015.06.019
   PubMed Web of Science ®Google Scholar
• Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/https://doi.org/10.1002/jcc.21334
   PubMed Web of Science ®Google Scholar
• Velázquez-Libera, J. L., Caballero, J., Toropova, A. P., & Toropov, A. A. (2019). Estimation of 2D autocorrelation descriptors and 2D Monte Carlo descriptors as a tool to build up predictive models for acetylcholinesterase (AChE) inhibitory activity. Chemometrics and Intelligent Laboratory Systems, 184, 14–21. https://doi.org/https://doi.org/10.1016/j.chemolab.2018.11.008
   Web of Science ®Google Scholar
• Verma, S., Kumar, A., Tripathi, T., & Kumar, A. (2018). Muscarinic and nicotinic acetylcholine receptor agonists: Current scenario in Alzheimer's disease therapy. The Journal of Pharmacy and Pharmacology, 70(8), 985–993. https://doi.org/https://doi.org/10.1111/jphp.12919
   PubMed Web of Science ®Google Scholar
• Veselinović, J. B., Nikolić, G. M., Trutić, N. V., Živković, J. V., & Veselinović, A. M. (2015). Monte Carlo QSAR models for predicting organophosphate inhibition of acetycholinesterase. SAR and QSAR in Environmental Research, 26(6), 449–460. https://doi.org/https://doi.org/10.1080/1062936X.2015.1049665
   PubMed Web of Science ®Google Scholar
• Vijayan, D. K., & Zhang, K. Y. J. (2019). Human glutaminyl cyclase: Structure, function, inhibitors and involvement in Alzheimer's disease. Pharmacological Research, 147, 104342. https://doi.org/https://doi.org/10.1016/j.phrs.2019.104342
   PubMed Web of Science ®Google Scholar